Lead Principal Scientist, Preventive Cancer Vaccines

BioSpace; Englewood (NJ); On-site; USD 165,000 - 215,000; Full time

Job summary

ICR is seeking a Principal Scientist to lead the Cancer Prevention Group, focusing on peptide-based cancer vaccines and immuno-oncology. The role requires a PhD or MD with 10+ years in vaccine development, including neoantigen strategies and immune monitoring.

You will guide end-to-end preclinical studies, collaborate with CROs and external experts, and advance programs toward human translation in the U.S. immunology community.

Qualifications

• PhD, MD or both with at least 10 years of vaccine development experience
• Experience researching personalized cancer vaccines including peptide-based and neoantigen-based approaches
• Experience with vaccine epitope identification, adjuvants, and immune response monitoring
• Experience with T cell receptor repertoire analysis, proliferation assays, cytokine release assays, and ELISPOT
• Expertise in cancer antigens, neoantigens, immuno-editing and immuno-monitoring
• Experience with vaccine delivery systems including peptide-, cell-, and viral-based systems
• Ability to manage CROs and external projects
• Strong collaboration with external KOLs and CROs; apply even if not all criteria met

Responsibilities

• Lead ICR's Cancer Prevention Group in researching and developing novel preventive cancer vaccines
• Drive end-to-end design, execution and interpretation of preclinical vaccine studies
• Collaborate with external KOLs and CRO partners to translate insights into first-in-class preventive vaccine programs

Skills

Leadership

Strategic research direction

Team collaboration

Scientific communication

Education

PhD or MD in relevant field

Job description

ICR is seeking a Principal Scientist to lead the Cancer Prevention Group, focusing on peptide-based cancer vaccines and immuno-oncology. The role requires a PhD or MD with 10+ years in vaccine development, including neoantigen strategies and immune monitoring.

You will guide end-to-end preclinical studies, collaborate with CROs and external experts, and advance programs toward human translation in the U.S. immunology community.